Preliminary investigation of the nasal delivery of liposomal leuprorelin acetate for contraception in rats.
The purpose of the study was to investigate the nasal route as a non-invasive alternative for delivery of leuprorelin acetate (leuprolide acetate, LEU) and to achieve an effective concentration of leuprorelin acetate in blood after nasal administration for contraception in rats. The plain drug solution, physical mixture (plain drug along with constituents of liposomes), or drug encapsulated in either neutral or charged liposomes containing 5 microg leuprorelin acetate were administered to rats through the nasal route. The plain drug solution was administered subcutaneously (s.c.). Simultaneous evaluation was performed on the influence of a mucoadhesive agent (chitosan) on nasal absorption of the plain drug and the liposome-encapsulated drug. Blood samples were taken at regular time intervals and subjected to luteinising hormone (LH) analysis using a specific immunoassay kit. The plasma luteinising hormone concentration vs time data of nasal and subcutaneous treatments were plotted and compared with that of subcutaneous administration. Relative percentage of bioavailability (F) for nasal treatments was calculated from plasma concentration vs time plots. Sperm count and fertility performance studies were carried out for selected formulations in rats. Neutral liposomes (LLEU) and negatively-charged liposomes (LLEUn) showed higher relative percentage of bioavailability (F 27.83 and 21.30%, respectively) as compared with the plain drug and the physical mixture (F 10.89 and 10.96%, respectively) after nasal administration. Hence, work on neutral liposomes was continued. F was further improved after incorporation of chitosan i.e. 10.89 to 49.13% for plain leuprorelin acetate and 27.83 to 88.90% for liposomal leuprorelin acetate formulations. Liposomal chitosan formulation administered nasally and leuprorelin acetate solution subcutaneously achieved complete azoospermia. No implantation sites were observed after the mating of female rats with treated males. It was observed that in the treated female rats, the estrous cycles ceased with the same formulations from the first treatment cycle. The findings of these investigations demonstrated that the bioavailability of the nasally-administered liposomal leuprorelin acetate with chitosan formulation was comparable with that of the subcutaneously administered drug. Complete contraception was obtained in male and female rats that had been treated with either the nasally administered liposomal leuprorelin acetate with chitosan or the subcutaneously administered drug.
Shahiwala
Aliasgar
A
Pharmacy Department, Faculty of Technology & Engineering, Kalabhavan, M. S. University of Baroda, Vadodara-390 001, Gujarat, India.
Misra
Ambikanandan
A
D000281:Administration, Intranasal; D000818:Animals; D048271:Chitosan; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D005260:Female; D005298:Fertility / Q000187:drug effects*; D016729:Leuprolide / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D008081:Liposomes; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008567:Membranes, Artificial; D009845:Oligospermia / Q000139:chemically induced; D051381:Rats; D013076:Sperm Count; D013092:Spermatogenesis-Blocking Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology
D003271:Contraceptive Agents, Female; D008081:Liposomes; D008567:Membranes, Artificial; D013092:Spermatogenesis-Blocking Agents; D007986:Luteinizing Hormone; D048271:Chitosan; D016729:Leuprolide